Stuart Arbuckle — Chief Commercial Officer and Executive Vice President at Vertex Pharmaceuticals

Mr. Stuart A. Arbuckle, B.Sc. has been the Chief Commercial Officer and an Executive Vice President at Vertex Pharmaceuticals Incorporated since September 4, 2012. Mr. Arbuckle joined Vertex in September 2012 and oversees Vertex's global commercial team, which is responsible for its sales, marketing, patient support, market research and other activities that support the approved use of Vertex's two medicines. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, he served multiple commercial leadership roles at Amgen, Inc. As Vice President and General Manager of Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen's portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp??, Neulasta?? and NEUPOGEN??, which accounted for more than $5 billion in sales in 2011 and led the successful launches of XGEVA?? and Nplate??. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in emerging markets, including countries in Asia, Africa and the Middle East. Prior to these roles, Mr. Arbuckle spent more than 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He has been a Director of Cerulean Pharma Inc. since June 26, 2015 and ImmunoGen, Inc since January 24, 2018. Mr. Arbuckle serves as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer. Mr. Arbuckle holds a Bachelor of Science with Honours in pharmacology and physiology from the University of Leeds in the United Kingdom.